Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine fumarate for remyelination in internuclear ophthalmoparesis in multiple sclerosis
NL-OMON52129Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Clemastine fumarate with Placebo (2 arms). Primary endpoint: Change in versional dysconjugacy index area under the curve. Started Aug 2022; status: recruiting.
02
Drugs
clemastine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON52129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52129.